Kroger Health has collaborated with Gauss to provide a smartphone-enabled, at-home Covid-19 rapid antigen test kit to patients in the US.

The Gauss COVID-19 Rapid Antigen Test kit is currently awaiting the emergency use authorisation (EUA) from the Food and Drug Administration (FDA).

It will provide patients with affordable access to new testing technology, which was developed by Gauss.

Following FDA’s authorisation, the solution is expected to be the first rapid Covid-19 test, which can be completed using a smartphone and a lateral flow assay without using a laboratory, a telemedicine visit, or any specialised electronics.

Additionally, Kroger is planning to make the Covid-19 test kit available for purchase on its website and at its 2,200 pharmacies across the US.

Kroger Health president Colleen Lindholz said: “Since the start of the Covid-19 pandemic, Kroger Heath has remained committed to helping people live healthier lives by offering a variety of Covid-19 testing solutions supported by our multi-disciplinary team of licensed, trained, and experienced healthcare providers.

“We’re proud to partner with Gauss to expand our COVIDCare+ suite with the forthcoming launch of this affordable, innovative solution.”

Developed by Gauss and biotechnology company Cellex, the test is powered by an encrypted, easy-to-use smartphone application.

Patients who need to use the test should follow video instructions in an application to properly collect the nasal swab and complete the rapid antigen test.

Using patent-pending, artificial intelligence-based technology, the app provides results to the patients in seconds and helps to reduce the reader variability.